Skip to main content
. 2021 Apr 24;20:89. doi: 10.1186/s12933-021-01283-w

Fig. 1.

Fig. 1

LDL-C levels and percentage of LDL-C reduction over time; data are number of patients (n) and percentage (%); grey bar = alirocumab, black bar = evolocumab. a Baseline LDL-C levels (n = 237), b LDL-C levels at month 3 (n = 227), c LDL-C levels at month 12 (n = 153); d % LDL-C reduction from baseline to month 3 (n = 227) e % LDL-C reduction from baseline to month 12 (n = 153)